Related references
Note: Only part of the references are listed.Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs
Yaquan Cao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
Zhangxu He et al.
ACTA PHARMACEUTICA SINICA B (2022)
MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer
Maria Dolores Fenor et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2022)
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Shang-Min Zhang et al.
NATURE (2021)
Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity
Xin-Hui Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance
Solenne Gaillard et al.
BIOLOGY OPEN (2021)
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)
Bing Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors
Liying Ma et al.
ACTA PHARMACEUTICA SINICA B (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis
Guoliang Li et al.
CANCER RESEARCH (2020)
Role of novel imaging in the management of prostate cancer
Karen M. Xu et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations
Xiaoni Liu et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Structure-based design and discovery of potent and selective KDM5 inhibitors
Zhe Nie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance
Wenxia Xu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2 '-Deoxycytidine
Benjamin R. Leadem et al.
CANCER RESEARCH (2018)
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
Pingzhao Zhang et al.
NATURE MEDICINE (2017)
The PI3K AKT pathway in the pathogenesis of prostate cancer
Xiaofei Wen
Frontiers in Bioscience-Landmark (2016)
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27
Dong Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression
Xudong Shen et al.
TUMOR BIOLOGY (2015)
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells
Bo Tang et al.
ONCOTARGET (2015)
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells
Yung-Ting Kuo et al.
PLOS ONE (2015)
Androgen receptor signaling in prostate cancer
Zoran Culig et al.
CANCER AND METASTASIS REVIEWS (2014)
Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma
Ling-Ling Sun et al.
ACTA HISTOCHEMICA (2013)
Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth
Yoshihiro Kano et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
The emerging role of histone lysine demethylases in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2012)
Molecular mechanisms and potential functions of histone demethylases
Susanne Marije Kooistra et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Inhibition of Histone Demethylases by 4-Carboxy-2,2′-Bipyridyl Compounds
Kai-Hsuan Chang et al.
CHEMMEDCHEM (2011)
Jumonji/ARID1 B (JARID1B) Protein Promotes Breast Tumor Cell Cycle Progression through Epigenetic Repression of MicroRNA let-7e
Doyel Mitra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
Alexander Roesch et al.
CELL (2010)
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway
Shinya Hayami et al.
MOLECULAR CANCER (2010)
Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis
Xi-Song Ke et al.
PLOS ONE (2009)
Non-coding RNAs, epigenetics and complexity
Fabricio F. Costa
GENE (2008)
RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells
Alexander Roesch et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer
Yang Xiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Share Paper
